Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · IEX Real-Time Price · USD
42.56
+1.70 (4.16%)
At close: May 3, 2024, 4:00 PM
42.50
-0.06 (-0.14%)
After-hours: May 3, 2024, 6:33 PM EDT
Celldex Therapeutics Employees
Celldex Therapeutics had 160 employees on December 31, 2023. The number of employees increased by 12 or 8.11% compared to the previous year.
Employees
160
Change (1Y)
12
Growth (1Y)
8.11%
Revenue / Employee
$43,019
Profits / Employee
-$883,931
Market Cap
2.81B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 160 | 12 | 8.11% |
Dec 31, 2022 | 148 | 14 | 10.45% |
Dec 31, 2021 | 134 | 9 | 7.20% |
Dec 31, 2020 | 125 | -5 | -3.85% |
Dec 31, 2019 | 130 | -7 | -5.11% |
Dec 31, 2018 | 137 | -60 | -30.46% |
Dec 31, 2017 | 197 | -13 | -6.19% |
Dec 31, 2016 | 210 | 11 | 5.53% |
Dec 31, 2015 | 199 | 38 | 23.60% |
Dec 31, 2014 | 161 | 32 | 24.81% |
Dec 31, 2013 | 129 | 17 | 15.18% |
Dec 31, 2012 | 112 | 9 | 8.74% |
Dec 31, 2011 | 103 | 3 | 3.00% |
Dec 31, 2010 | 100 | 7 | 7.53% |
Dec 31, 2009 | 93 | 12 | 14.81% |
Dec 31, 2008 | 81 | 28 | 52.83% |
Dec 31, 2007 | 53 | -33 | -38.37% |
Dec 31, 2006 | 86 | 13 | 17.81% |
Dec 31, 2005 | 73 | 11 | 17.74% |
Dec 31, 2004 | 62 | 3 | 5.08% |
Dec 31, 2003 | 59 | -7 | -10.61% |
Dec 31, 2002 | 66 | -5 | -7.04% |
Dec 31, 2001 | 71 | 5 | 7.58% |
Dec 31, 2000 | 66 | 16 | 32.00% |
Dec 31, 1999 | 50 | -3 | -5.66% |
Dec 31, 1998 | 53 | 17 | 47.22% |
Dec 31, 1997 | 36 | -7 | -16.28% |
Dec 31, 1996 | 43 | -14 | -24.56% |
Dec 31, 1995 | 57 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Neogen | 2,640 |
Certara | 1,391 |
PTC Therapeutics | 995 |
GoodRx Holdings | 694 |
MorphoSys AG | 524 |
TG Therapeutics | 264 |
Merus | 229 |
Rhythm Pharmaceuticals | 226 |
CLDX News
- 18 days ago - Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria - GlobeNewsWire
- 2 months ago - Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference - GlobeNewsWire
- 2 months ago - Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Celldex Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria - GlobeNewsWire